Imugene Ltd (IMU) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Imugene Ltd stock A$0.03, price A$0.03, upside +0.0%, quality 21 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Imugene Ltd
IMU · AUThe stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range A$0.0300 – A$20.57 · fair‑value band A$0.0305 – A$0.0356 · the A$0.0330 price screens below the A$0.0330 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Imugene is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.
Show moreShow less
Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study.
The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer.
Imugene Limited is headquartered in Sydney, Australia.
Stock analysis
Imugene Ltd (IMU) currently trades at A$0.0330, while our estimate is A$0.0330, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: A$0.0305 (bear) to A$0.0356 (bull), the price of A$0.0330 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Imugene Ltd reported revenue of A$4.4M in FY2025 versus A$7.2M in FY2021, a compound −11.7%/yr. Reported net income was −A$105M in FY2026.
Key figures
Market cap A$18.3M (≈ $12.3M) Micro · P/S ratio 10.1 · EPS (TTM) A$−0.3200 · Return on equity −314% · Return on assets (EBIT) −113% (5-year average) · Operating margin −5,246% · Revenue (TTM) A$2.1M · Revenue growth (YoY) −59.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 56 out of 100 (low confidence).
What moves the price
The share trades about 92% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 0%, IMU screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch IMU, get fair value alerts →
Compare Imugene Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EV/EBITDA by industry
- Dividend yield by industry
- PEG screener for stocks with fair value
- Valuation of the Australia market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs IMU |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs IMU |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs IMU |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs IMU |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs IMU |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs IMU |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs IMU |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs IMU |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs IMU |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs IMU |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Imugene Ltd (IMU) overvalued or undervalued?
What is the fair value of IMU?
What is the quality score of IMU?
What is the price target for Imugene Ltd (IMU)?
What is the Imugene Ltd stock forecast for 2026?
What is the revenue of Imugene Ltd (IMU)?
What is the intrinsic value of Imugene Ltd (IMU)?
Is Imugene Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of IMU?
How much is Imugene Ltd worth?
What do the bullish and bearish scenarios say about IMU?
What is the PEG ratio of IMU?
How solid is the balance sheet of Imugene Ltd (IMU)?
How far is IMU from its 52-week high?
Which stocks are comparable to Imugene Ltd?
Is Imugene Ltd stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Imugene Ltd (IMU)?
What should I pay attention to with Imugene Ltd right now?
Key figures of Imugene Ltd
How large is the market capitalisation of Imugene Ltd (IMU)?
What is the P/S ratio of Imugene Ltd (IMU)?
What are the earnings per share of Imugene Ltd (IMU)?
What is the return on equity of Imugene Ltd (IMU)?
What is the EBIT return on assets of Imugene Ltd (IMU)?
What is the operating margin of Imugene Ltd (IMU)?
How fast is revenue growing at Imugene Ltd (IMU)?
How much free cash flow does Imugene Ltd (IMU) generate?
How much net debt does Imugene Ltd (IMU) carry?
Watch Imugene Ltd in the live analysis
One click puts Imugene Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.